News

Deal Announcements

Symic Biomedical Clears $25 Million Series A-2

Wednesday, December 2, 2015 5:40:00 AM PDT | VentureDeal
   San Francisco, California  --  Biotherapeutics company Symic Biomedical has received $25 million in Series A-2 venture capital and strategic investment.

Symic is developing multiple compounds that target the extracellular matrix.

The round was led by Lilly Ventures (Dr. Armen Shanafelt) and featured all existing major investors as well as new investors.

The company said it would use the funding to advance its pipeline of leading candidates SB-030 and SB-061.

SB-030 is a locally applied single use treatment for the reduction of acute inflammation resulting from the vascular injury following percutaneous transluminal angioplasty.

SB-061 is an osteoarthritis treatment candidate.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1